PDT Partners takes $3.35M stake in West Pharmaceutical as earnings beat estimates
What's the deal? PDT Partners LLCDealroom has a profile for this one. Try Dealroom → bought a new position in West Pharmaceutical ServicesDealroom has a profile for this one. Try Dealroom → during the second quarter, picking up 9,332 shares worth roughly $3,350,000. The medical instruments supplier makes packaging and delivery systems for injectable drugs.
Why now? The disclosure follows a strong quarter. West reported earnings of $2.37 per share for the period ended July 23, 2026, topping the $2.08 consensus by $0.29, while revenue rose 13.8% year over year to $872.30 million — above the $839.98 million analysts expected.
By the numbers: The company posted a return on equity of 20.11% and a net margin of 16.98%. It carries a market cap of $24.68 billion, a debt-to-equity ratio of 0.07, and a PE ratio of 44.90.
What's next? West guided to full-year 2026 earnings of $8.85 to $9.05 per share, with analysts projecting $8.93. It also declared a quarterly dividend of $0.22, paid August 5, for an annualised yield of 0.3%.
The signal: Institutional confidence remains high — 93.90% of the stock is institutionally owned, and analysts hold a "Moderate Buy" consensus with a $368.08 average price target. BarclaysDealroom has a profile for this one. Try Dealroom → recently upgraded the stock to "overweight" and lifted its target to $400.00, one of several bullish moves as shares trade near $350.68, within a 52-week range of $223.83 to $386.00.
Read more: tickerreport.com
